A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma

NOT ENROLLING
Protocol # :
19-671
Conditions
Neuroblastoma
Phase
I
Disease Sites
Brain and Nervous System
Principal Investigator
Shusterman, Suzanne

Trial Description

The reason for this study is to see if the study drug LY3295668 erbumine is safe in
participants with relapsed/refractory neuroblastoma.

Eligibility Requirements

Inclusion Criteria:

- Participants must have relapsed/refractory neuroblastoma and have active disease in
at least one site: bone, bone marrow or soft tissue. Participants must be able to
submit an archival sample of tissue.

- Participants must be able to swallow capsules.

Exclusion Criteria:

- Participants must not have had an allogeneic hematopoietic stem cell, bone marrow,
or solid organ transplant.

- Participants must not have untreated tumor that has spread to the brain or spinal
cord.

- Participants must not have a serious active disease other than neuroblastoma.

- Participants must not have a condition affecting absorption.

- Participants must not have had prior aurora kinase inhibitor exposure.

- Participants must not have a known allergy to the study treatment.

- Participants must not have symptomatic human immunodeficiency virus (HIV) infection
or symptomatic activated/reactivated hepatitis A, B, or C.

19-671